Orexo R&D Day on Strategy and AmorphOX
Analysis based on 8 articles · First reported Mar 06, 2026 · Last updated Mar 06, 2026
The R&D Day by Orexo is expected to positively impact its stock price by providing clarity on its future strategy and pipeline, particularly the Orexo===AmorphOX technology and product candidates Orexo===OX640 and Orexo===OX390. This event could attract investor attention to the pharmaceutical sector, especially companies focused on drug delivery innovation and emergency medications.
Orexo AB is hosting an R&D Day on March 24, 2026, in Stockholm, Sweden, to present its updated strategy and R&D priorities. CEO Nikolaj Sørensen and the management team will highlight the company's proprietary drug delivery technology, Orexo===AmorphOX, and its role in driving future development. The agenda includes discussions on pipeline products Orexo===OX640, an intranasal epinephrine candidate for allergic reactions, and Orexo===OX390, a rescue medication for adulterated overdoses, developed in collaboration with United States===Biomedical Advanced Research and Development Authority. Expert Mark A. Smith will also speak on emerging threats from xylazine, medetomidine, and fentanyl combinations, underscoring the need for products like Orexo===OX390. This event follows Orexo's divestment of Orexo===Buprenorphine/naloxone in the US.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard